VERAXA Biotech (NASDAQ: VRXA) has taken a significant step forward in the development of its lead cancer therapy, receiving favorable Scientific Advice from Germany’s Paul-Ehrlich-Institute (PEI). The regulatory guidance, which addresses the biological rationale, pharmacokinetics, and planned non-clinical safety studies for the company’s lead BiTAC-TCE therapy, marks an early validation of the development strategy and could reduce uncertainty as the program moves toward clinical trials.
BiTAC-TCE is a next-generation bispecific T-cell engager designed to selectively target cancer cells that carry two specific biomarkers, while sparing cells with only one. This dual-targeting approach has the potential to improve the therapeutic window compared to conventional T-cell engagers, which often attack cells with a single biomarker, leading to on-target, off-tumor toxicity. VERAXA’s preclinical results, presented at the 2026 AACR Annual Meeting, demonstrated this selective targeting, showing activity against cancer cells with both biomarkers while leaving single-positive cells unharmed.
The PEI’s feedback is crucial as it provides regulatory clarity on the non-clinical studies needed to support an Investigational New Drug (IND) application or equivalent. By aligning on the biological rationale and pharmacokinetics, VERAXA can now focus on completing these studies with confidence, potentially shortening the timeline to first-in-human trials. The guidance also reduces development risk, as early regulatory alignment often helps avoid costly delays later in the process.
“We are pleased with the favorable Scientific Advice from the PEI, which underscores the potential of our BiTAC platform,” said a company spokesperson. “This guidance helps us refine our development path and progress our lead program efficiently toward the clinic.”
Beyond the lead program, VERAXA is building a broader oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody therapies. The company leverages a suite of transformative technologies and quality-by-design principles to advance these candidates. Its scientific foundation stems from breakthroughs made at the European Molecular Biology Laboratory, a renowned institution for life science research.
The successful regulatory engagement is a positive signal for the company and the broader oncology community, as it highlights the growing interest in more precise cancer immunotherapies. If the BiTAC-TCE therapy proves successful in clinical trials, it could offer a new treatment option for patients with cancers that express the target biomarkers, potentially improving outcomes while minimizing side effects.
Investors and stakeholders will be watching closely as VERAXA completes its non-clinical studies and manufacturing scale-up. The company’s ability to execute on its development plan will be critical in the coming months. For more information on the full article, visit https://ibn.fm/U4ON1.
VERAXA Biotech AG is building a premier engine for the discovery and development of next-generation antibody-based therapeutics. Its pipeline includes bispecific T-cell engagers, bispecific ADCs, and other innovative formats. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory and is committed to rigorous quality-by-design principles. For regular updates about VERAXA Biotech, visit www.VERAXA.com.
